These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 21074058)

  • 1. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of immune-related adverse events and kinetics of response with ipilimumab.
    Weber JS; Kähler KC; Hauschild A
    J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
    Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
    Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Mössner R; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2016 Jul; 14(7):662-81. PubMed ID: 27373241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab for advanced melanoma: a nursing perspective.
    Ledezma B
    Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma].
    Lotem M; Merims S; Frank S; Ospovat I; Peretz T
    Harefuah; 2012 Oct; 151(10):585-8, 604. PubMed ID: 23316667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibody therapies for melanoma].
    Kiniwa Y; Okuyama R
    Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
    Weber J
    Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CTLA-4 antibody adjuvant therapy in melanoma.
    Eggermont AM; Testori A; Maio M; Robert C
    Semin Oncol; 2010 Oct; 37(5):455-9. PubMed ID: 21074060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
    Berman D; Parker SM; Siegel J; Chasalow SD; Weber J; Galbraith S; Targan SR; Wang HL
    Cancer Immun; 2010 Nov; 10():11. PubMed ID: 21090563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
    Klein O; Ebert LM; Nicholaou T; Browning J; Russell SE; Zuber M; Jackson HM; Dimopoulos N; Tan BS; Hoos A; Luescher IF; Davis ID; Chen W; Cebon J
    Clin Cancer Res; 2009 Apr; 15(7):2507-13. PubMed ID: 19318477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
    Bakacs T; Mehrishi JN; Moss RW
    Immunobiology; 2012 Jun; 217(6):583-9. PubMed ID: 21821307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab: a promising immunotherapy for melanoma.
    Thumar JR; Kluger HM
    Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
    Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
    J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.